933.85
-0.90%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shilpa Medicare
Its shares trade on NSE under the ticker SHILPAMED.NS. It has been listed since 31 March 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹15.39bn and net income of ₹2.43bn. At that date it held total assets of ₹37.06bn and shareholders' equity of ₹25.91bn.
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical products and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. The company is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 31 Mar 1995
- Employees
- 1,033
- Website
- vbshilpa.com ↗
Leadership
Pay as last reported
- Mr. Omprakash InaniNon-Executive Chairman of the Board₹600,000
- Mr. Alpesh DalalChief Financial Officer₹14.8m
- Ms. Ritu TiwaryCompliance Officer, Company Secretary₹5.6m
- Mr. Vishnukant BhutadaManaging Director, Executive Director₹35.0m
- Mr. Kalakota ReddyWhole-Time Director, since 2019₹18.0m
- Mr. Ashraf Loutfy Abdelhamid AllamNon-Executive Independent Director
- Dr. Anita BandyopadhyayNon-Executive Independent Women Director₹1.8m
- Mr. Hetal GandhiNon-Executive Independent Director₹5.0m
- Dr. Kamal SharmaNon-Executive Independent Director₹3.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 71
- Environment
- 85
- Social
- 74
- Governance
- 53
- Direct emissions (scope 1)
- 3,690.31 t
- Energy emissions (scope 2)
- 20,389.9 t
- Women in the workforce
- 3.97219%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Manufactures oncology and non-oncology APIs and formulations
- Supplies oncology APIs and intermediates to regulated markets
- Produces Lenvatinib Capsules under the brand name Lenshil
Weaknesses
- Engages in wind power generation which may divert focus from core pharmaceutical business
- Limited product range for non-oncology APIs in specific markets
- No mention of R&D investment or innovation in provided data
Opportunities
- Expansion into emerging markets for oncology APIs and intermediates
- Growth potential in biosimilars and ophthalmic products
- Potential to increase market share in oncology formulations
Threats
- Competition in the pharmaceutical industry for API supply
- Regulatory challenges in multiple international markets
- Dependence on specific API products like Capecitabine and Gemcitabine
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.